Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis (ReBUILD)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
University of California, San Francisco
ClinicalTrials.gov Identifier:
NCT02040298
First received: January 10, 2014
Last updated: April 14, 2016
Last verified: April 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2016
  Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)